Voyager Therapeutics Files 8-K on Financials
Ticker: VYGR · Form: 8-K · Filed: Mar 11, 2025 · CIK: 1640266
Sentiment: neutral
Topics: financial-condition, results-of-operations, filing
Related Tickers: VYGR
TL;DR
Voyager Therapeutics dropped an 8-K on March 11th detailing their financial condition. Check it out.
AI Summary
Voyager Therapeutics, Inc. filed an 8-K on March 11, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 75 Hayden Avenue, Lexington, Massachusetts.
Why It Matters
This filing provides an update on Voyager Therapeutics' financial performance and condition, which is crucial for investors to assess the company's stability and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing (8-K) and does not appear to contain any new material events or significant negative news.
Key Players & Entities
- Voyager Therapeutics, Inc. (company) — Registrant
- March 11, 2025 (date) — Date of Report
- 75 Hayden Avenue Lexington, Massachusetts 02421 (address) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Voyager Therapeutics, Inc.'s results of operations and financial condition, and to include financial statements and exhibits.
When was this 8-K filing submitted?
This 8-K filing was submitted on March 11, 2025.
Where are Voyager Therapeutics, Inc.'s principal executive offices located?
Voyager Therapeutics, Inc.'s principal executive offices are located at 75 Hayden Avenue, Lexington, Massachusetts, 02421.
What is the SIC code for Voyager Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Voyager Therapeutics, Inc. is 2836, which corresponds to BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
What is the company's state of incorporation?
Voyager Therapeutics, Inc. is incorporated in Delaware.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 11, 2025 regarding Voyager Therapeutics, Inc. (VYGR).